Denis B Buxton

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Calcium-dependent threonine phosphorylation of nonmuscle myosin in stimulated RBL-2H3 mast cells
    D B Buxton
    Laboratory of Molecular Cardiology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 275:34772-9. 2000
  2. ncbi request reprint Induction of nonmuscle myosin heavy chain II-C by butyrate in RAW 264.7 mouse macrophages
    Denis B Buxton
    Laboratory of Molecular Cardiology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 278:15449-55. 2003
  3. ncbi request reprint Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group
    Denis B Buxton
    Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 108:2737-42. 2003
  4. ncbi request reprint Nanotechnology in the diagnosis and management of heart, lung and blood diseases
    Denis B Buxton
    National Heart, Lung, and Blood Institute, Advanced Technologies and Surgery Branch, Division of Cardiovascular Diseases, Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 7:149-60. 2007
  5. doi request reprint Nanomedicine for the management of lung and blood diseases
    Denis B Buxton
    Advanced Technologies and Surgery Branch, Division of Cardiovascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Nanomedicine (Lond) 4:331-9. 2009
  6. doi request reprint Current status of nanotechnology approaches for cardiovascular disease: a personal perspective
    Denis B Buxton
    National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892 7940, USA
    Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:149-55. 2009
  7. ncbi request reprint A single class II myosin modulates T cell motility and stopping, but not synapse formation
    Jordan Jacobelli
    Department of Pathology, University of California at San Francisco, 513 Parnassus Ave, San Francisco, California 93143, USA
    Nat Immunol 5:531-8. 2004

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Calcium-dependent threonine phosphorylation of nonmuscle myosin in stimulated RBL-2H3 mast cells
    D B Buxton
    Laboratory of Molecular Cardiology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 275:34772-9. 2000
    ..These data indicate a role for CaM kinase stimulation and resultant threonine phosphorylation of NMHC-IIA in RBL-2H3 m1 cell activation...
  2. ncbi request reprint Induction of nonmuscle myosin heavy chain II-C by butyrate in RAW 264.7 mouse macrophages
    Denis B Buxton
    Laboratory of Molecular Cardiology, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 278:15449-55. 2003
    ..8-Bromo-cGMP had no effect on nonmuscle myosin heavy chain induction, consistent with a cGMP-independent mechanism for nitric oxide-mediated inhibition of nonmuscle myosin heavy chain II-C induction...
  3. ncbi request reprint Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group
    Denis B Buxton
    Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 108:2737-42. 2003
    ..Finally, encouragement of small businesses to develop nanotechnology-based approaches to clinical problems was considered important...
  4. ncbi request reprint Nanotechnology in the diagnosis and management of heart, lung and blood diseases
    Denis B Buxton
    National Heart, Lung, and Blood Institute, Advanced Technologies and Surgery Branch, Division of Cardiovascular Diseases, Bethesda, MD 20892, USA
    Expert Rev Mol Diagn 7:149-60. 2007
    ..The goal is to summarize the current state of science and technology in these areas and to look at future directions that the field is likely to move in to enhance the diagnosis and treatment of heart, lung and blood diseases...
  5. doi request reprint Nanomedicine for the management of lung and blood diseases
    Denis B Buxton
    Advanced Technologies and Surgery Branch, Division of Cardiovascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Nanomedicine (Lond) 4:331-9. 2009
    ..Treatment of both lung and blood diseases is also likely to benefit from nano-scaffold-based methods for controlling the differentiation and proliferation of stem and progenitor cells...
  6. doi request reprint Current status of nanotechnology approaches for cardiovascular disease: a personal perspective
    Denis B Buxton
    National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892 7940, USA
    Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:149-55. 2009
    ..Taken together, these new technologies have enormous potential for improving the diagnosis and treatment of cardiovascular diseases...
  7. ncbi request reprint A single class II myosin modulates T cell motility and stopping, but not synapse formation
    Jordan Jacobelli
    Department of Pathology, University of California at San Francisco, 513 Parnassus Ave, San Francisco, California 93143, USA
    Nat Immunol 5:531-8. 2004
    ..Phosphorylation of MyH9 in its multimerization domain by T cell receptor-generated signals indicates that inactivation of this motor may be a key step in the 'stop' response during antigen recognition...